by Ethan Perlstein | Nov 13, 2015 | Last Month in Tweets |
Over the summer we completed the hit-to-lead phase of our NPC discovery program, and in the fall we commenced mouse validation studies with PERL101, our most promising hit from the nematode and fly primary screens. First mouse PK data (IV and PO) are in! —...
by Ethan Perlstein | Oct 20, 2015 | Last Month in Tweets |
Last month we achieved a major scientific milestone — our first mouse pharmacokinetics (PK) data show metabolic stability of our most promising lead compound. We were busy with conference travel, and we started rolling out blogs on a more consistent basis. The...
by Ethan Perlstein | Sep 10, 2015 | Last Month in Tweets |
Coinciding with the end of summer, we wrapped up the hit validation phase of our NPC lead discovery program. In 9 months, we whittled 50,o00 lead-like library compounds down to ~1,000 primary screening hits, which in turn we further winnowed down to ~100 fully...
by Ethan Perlstein | Aug 14, 2015 | Last Month in Tweets |
July marked the transition from the primary screening phase of our Niemann-Pick C drug discovery campaign to the hit validation phase. And lots more happenings in and around the lab. Our Med Chem advisor @JohnTuckerPhD is in the lab today reviewing hits from our NPC...
by Ethan Perlstein | Jul 18, 2015 | Last Month in Tweets |
Last month’s highlight was that we completed the primary screening phase of our NPC lead program. Let’s take a closer look at how summer started at PLab. Prices of orphan drugs for monogenic diseases are skyrocketing while approvals are flat — both...
by Ethan Perlstein | Jun 16, 2015 | Last Month in Tweets |
Last month we were diligently completing the primary screening phase of our NPC campaign: 50,000 compounds across 3 models in 6 months. Our NPC worm screen is nearing the home stretch. pic.twitter.com/eBOTpUq1N9 — Perlara (@PerlaraPBC) May 1, 2015 Team Worm...
